Outset Medical Inc Dossier - Source-backed chat

Outset Medical Inc

OMNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)1.63

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $3.75Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $70.5M

Enterprise Value $133.1M

Shares Outstanding 21.3M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Outset Medical is transitioning from a high-burn development phase to a high-margin commercial execution phase, anchored by its innovative Tablo Hemodialysis System. The recent FDA clearance of its next-generation Tablo platform in early 2026, which features industry-leading cybersecurity compliance, provides a strong competitive moat. With recurring revenues representing approximately 70-80% of the total mix and gross margins expanding significantly to over 43%, the company is well-capitalized with $161 million in cash to reach cash flow breakeven.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$6.00

Mean target$7.67

High · most bullish analyst$10.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.5015%

Sales cycle execution delays, hospital capital budget constraints, or competitive pressures from larger players like Fresenius and Baxter limit revenue growth to flat year-over-year (< $120M). Gross margins compress back to the high-30% range due to under-absorption.

Base CaseCentral scenario

$8.3365%

The company successfully launches the next-generation Tablo platform in Q2 2026, driving steady adoption across acute and home care settings. Revenue meets the full-year guidance of $125M-$130M, and gross margins stabilize in the mid-40% range, narrowing net losses significantly.

Bull CaseUpside scenario

$10.0025%

The next-generation Tablo platform experiences rapid, higher-than-expected adoption due to its unique cybersecurity features, driving full-year 2026 revenue above the high end of guidance ($130M+). Gross margins expand rapidly toward the 50% target, and the company achieves cash flow breakeven ahead of schedule.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Highly predictable recurring revenue model with consumables and services comprising ~70-80% of total sales.
Significant gross margin expansion, reaching a record 43.4% in Q1 2026, driven by product cost reductions and service margin improvements.
First-mover advantage with the next-generation Tablo platform, which is the first dialysis system cleared under the FDA's strict cybersecurity guidelines.
Strong balance sheet with $161 million in cash and cash equivalents, providing a clear runway to self-funded profitability.

Key Investment Risks

Long and variable sales cycles for capital equipment in hospital settings.
Intense competition from well-entrenched, larger industry giants such as Fresenius Medical Care and Baxter International.
Regulatory risks associated with ongoing FDA compliance and future 510(k) submissions.
Execution risk in scaling the home dialysis market, which requires extensive patient and physician education.

Thesis Invalidation Triggers

Failure of the next-generation Tablo platform to gain commercial traction in Q2/Q3 2026.
A material downward revision of the FY 2026 revenue guidance below $120 million.
Significant cash burn acceleration that threatens the runway to cash flow breakeven without highly dilutive financing.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.